A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: Contrast-enhanced ultrasonography and histological examination
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: Contrast-enhanced ultrasonography and histological examination
Authors
Keywords
-
Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 107, Issue 2, Pages 155-159
Publisher
Wiley
Online
2012-08-17
DOI
10.1002/jso.23244
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chemotherapy Before Liver Resection of Colorectal Metastases
- (2011) Kuno Lehmann et al. ANNALS OF SURGERY
- Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases
- (2011) Hannes P. Neeff et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab
- (2010) Dietmar Tamandl et al. ANNALS OF SURGERY
- Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis
- (2010) Laura Rubbia-Brandt et al. HISTOPATHOLOGY
- Reversibility of capillary density after discontinuation of bevacizumab treatment
- (2009) N. Steeghs et al. ANNALS OF ONCOLOGY
- Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
- (2009) M. Klinger et al. EJSO
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
- (2009) Yun Shin Chun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact of Preoperative Bevacizumab on Complications After Resection of Colorectal Liver Metastases: Case-Matched Control Study
- (2009) Mahfud Mahfud et al. WORLD JOURNAL OF SURGERY
- Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?
- (2008) René Adam et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases
- (2008) Susan B. Kesmodel et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
- (2008) Dan G. Blazer et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
- (2008) Brigit Gruenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapies and surgical issues in gastrointestinal cancers
- (2008) Alexander A. Parikh et al. Targeted Oncology
- Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases
- (2007) Srinevas K. Reddy et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search